Rubicon Research
RUBICON
Pharma₹1628.00
price as of 3/10/2026, 12:13:02 am
Market cap ₹26,949 Cr
- P/E
- 93.30
- Day range
- ₹1,605.20 – ₹1,670.00
- 52-week range
- ₹570.75 – ₹1,899.00
- Volume
- 1.54 L
- Open
- ₹1,635.70
- Prev close
- ₹1,619.40
1 red flag to read up on
- high
Under Additional surveillance (ASM)
The exchange has put this stock under Additional surveillance (ASM), Stage I · 2 Oct 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
RUBICON in NSE indices and F&O
Research profile
Derived metrics
- Earn. yield
- 1.1%
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 44 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹432.1K Cr | 35.71 | 5.18 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹245.5K Cr | 83.82 | 14.66 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹181.3K Cr | 76.11 | 19.22 | 26.8% | 15.0% | 34.0% | 1.79 | +54.8% |
| Apollo HospitalsAPOLLOHOSP | ₹116.9K Cr | 56.14 | 13.60 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| Zydus LifesciencesZYDUSLIFE | ₹114.3K Cr | 25.57 | 4.26 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| CiplaCIPLA | ₹108.6K Cr | 32.26 | 3.20 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Laurus LabsLAURUSLABS | ₹107.2K Cr | 98.02 | 20.20 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| Rubicon ResearchRUBICON | ₹26.9K Cr | 93.30 | — | — | — | — | — | — |
| Sector median | ₹45.8K Cr | 49.95 | 5.80 | 14.6% | 16.0% | 22.5% | 0.31 | +17.1% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Financials not yet synced
This company is tracked, but its filings have not been processed yet. Results appear here once the next sync reaches it.
Corporate actions
No dividends, splits or bonuses recorded for this company yet.
FAQ
Rubicon Research: common questions
Answered from the figures on this page.
Rubicon Research last traded at ₹1,628.00 (NSE, as of 3 Oct 2026). The last session moved it up 0.53%.
Rubicon Research is valued at about ₹26,949 crore (NSE, as of 3 Oct 2026).
Rubicon Research trades at a price-to-earnings ratio of 93.30 (NSE, as of 3 Oct 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.
Rubicon Research has traded between ₹570.75 and ₹1,899.00 over the past 52 weeks, to 3 Oct 2026. It is currently 80% of the way up that range.
Rubicon Research (RUBICON) is classified under Pharma on this site's screener.
